Agios director John Maraganore resigns; Catherine Owen elected to board

AGIOS PHARMACEUTICALS, INC.

John Maraganore resigned from board effective May 24, 2023, after nearly 12 years.
Kaye Foster appointed lead independent director; Cynthia Smith becomes Compensation & People Committee chair.
Catherine Owen elected as class II director effective June 13, 2023; joins Compensation & People Committee.
Owen receives annual cash: $50,000 as director plus $7,500 for committee service.
Owen granted initial equity: nonstatutory option with $472,500 Black-Scholes value and RSUs valued at $157,500.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

John Maraganore

Director

AGIO · AGIOS PHARMACEUTICALS, INC.

Effective: 2023-05-24
Filed: May 25, 2023, 7:59 PM ET

John Maraganore, Ph.D., notified Agios Pharmaceuticals, Inc. (the “Company”) of his decision to resign from the Board of Directors of the Company (the “Board”), effective May 24, 2023

Appointed

Catherine Owen

Director

AGIO · AGIOS PHARMACEUTICALS, INC.

Effective: 2023-06-13
Filed: May 25, 2023, 7:59 PM ET

elected Catherine Owen as a director, effective as of June 13, 2023

Appointed

Kaye Foster

Lead Independent Director

AGIO · AGIOS PHARMACEUTICALS, INC.

Effective: 2023-05-24
Filed: May 25, 2023, 7:59 PM ET

appointed director Kaye Foster to serve as the Board’s lead independent director

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

John Maraganore resigned as Director at AGIOS PHARMACEUTICALS, INC..

Action: resigned
Role: Director

Exact text from the filing

John Maraganore, Ph.D., notified Agios Pharmaceuticals, Inc. (the “Company”) of his decision to resign from the Board of Directors of the Company (the “Board”), effective May 24, 2023

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Catherine Owen was elected as Director at AGIOS PHARMACEUTICALS, INC..

Action: elected
Role: Director

Exact text from the filing

elected Catherine Owen as a director, effective as of June 13, 2023

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.8

Kaye Foster was appointed as Lead Independent Director at AGIOS PHARMACEUTICALS, INC..

Action: appointed
Role: Lead Independent Director

Exact text from the filing

appointed director Kaye Foster to serve as the Board’s lead independent director

View on SEC.gov

AGIOS PHARMACEUTICALS, INC. filing history →

Source: SEC EDGAR

accession 0001193125-23-154190

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.